Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | Ibrutinib updates from ASH 2016

Peter Hillmen • 9 Dec 2016
ASH 2016
Chronic Lymphocytic Leukemia Chlorambucil Ibrutinib
RESONATE-2

Peter Hillmen, MBChb, PhD, FRCP, FRCPath of St. James’ University Hospital, Leeds, UK discusses the update on ibrutinib for chronic lymphocytic leukemia (CLL) presented at the 2016 Annual Meeting of the American Society of Hematology, held in San Diego, CA. The RESONATE-2 trial looked at frontline ibrutinib compared with chlorambucil (NCT01722487). Prof. Hillmen explains that the updated data are looking very positive with patients randomized to ibrutinib having good progression-free survival (PFS). Further, the five-year update of a small Phase II trial of single agent ibrutinib also shows durable remissions (NCT01105247).

More from Peter Hillmen

1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals